Survival Analysis and Immunohistochemical Study of HER-2 and AR (Androgen Receptor) Expression in Salivary Duct Carcinoma

Abstract

Frequent expressions of HER-2 and AR in SDC suggest that these receptors can be suitable molecular targets of systemic therapy for patients with SDC in which distant metastasis seems to be the largest obstacle to improving survival. In order to assess the efficacy of anti-HER-2 therapy and anti-androgen therapy for each receptor-positive SDC, a multi-institutional joint research system should be organized.